BeiGene (NASDAQ: BGNE)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
BeiGene Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
BeiGene Company Info
BeiGene, Ltd. American Depositary Shares
News & Analysis
The Chinese pharmaceutical stock is experiencing a comeback.
BeiGene's shares are down this year, but it has two potential blockbusters.
Regulators in China agreed to start the review process for one of its medicines.
The most critical hurdle confronting the biotech is avoiding having its shares delisted by the SEC.
The Chinese pharmaceutical company saw a bounce back after positive news from government officials.
The threat of a forced delisting is weighing heavily on these two Chinese biotech stocks.
The Chinese pharmaceutical company is racking up approvals for its lead oncology drug, Brukinsa.
There are plenty of risks, but the rewards could be great.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 03/30/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.